MK-3697 Size:Solid 10 mg Approximately 1 month after treatment

Approximately 1 month after treatment initiation

CAS Number: 89464-63-1

Short-term Salbutamol intake did appear to improve performance during intense submaximal exercise with concomitant increase in substrate availability and utilization

3-b]pyridin-3-yl)acetic acid

19R)-11-(acetyloxy)-4-[(12S

MK-3697 Size:Solid 10 mg Approximately 1 month after treatmentMK 3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists . MK 3697 is also the third insomnia drug, currently being developed by Merck. MK 3697 has Ki = 0. 95 nM. Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. In vivo tests results on MK 3697 demonstrated improved stability and TDI profiles as well as excellent sleep efficacy across species. Product information CAS Number: